Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
The trial did not meet its primary endpoint, although 18% of patients with non-ACC treated with immune priming followed by cisplatin plus elraglusib achieved a response. Higher nGSK-3β expression was observed in tumor samples obtained from responders.
Authors
- Michael J. Dennis (ORCID: https://orcid.org/0000-0002-8175-5311)
- Kee‐Young Shin (ORCID: https://orcid.org/0000-0002-3451-8516)
- Vickie Y. Jo (ORCID: https://orcid.org/0000-0003-4808-2714)
- Veronica Bedard
- Glenn J. Hanna (ORCID: https://orcid.org/0000-0002-9969-2523)
- Kristine Wong (ORCID: https://orcid.org/0000-0003-4139-1581)
- Kartik Sehgal (ORCID: https://orcid.org/0000-0003-4391-6943)
- A. O’Neill (ORCID: https://orcid.org/0009-0002-7334-4560)
- Andrey Ugolkov (ORCID: https://orcid.org/0000-0002-4029-0933)
- Andrew P. Mazar (ORCID: https://orcid.org/0009-0000-3681-6704)
- Robert I. Haddad (ORCID: https://orcid.org/0000-0003-1413-0079)
- Nicole Scarfo (ORCID: https://orcid.org/0009-0003-9512-1015)
Institutions
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Fate Therapeutics (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2731
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gateway for Cancer Research
- Pfizer
- Adenoid Cystic Carcinoma Research Foundation
- Exelixis
- Actuate Therapeutics
- Genentech